Levilimab Biosimilar – Anti-IL6R mAb – Research Grade from ProteoGenix; catalogue PX-TA1545; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Levilimab Biosimilar is a monoclonal antibody (mAb) that targets the interleukin-6 receptor (IL6R). It is a research grade antibody that has shown promising results in pre-clinical and clinical studies as a potential therapeutic for various inflammatory and autoimmune diseases. In this article, we will dive into the structure, activity, and potential applications of Levilimab Biosimilar.
Levilimab Biosimilar is a biosimilar version of the anti-IL6R mAb, tocilizumab. It is a fully humanized IgG1 kappa monoclonal antibody with a molecular weight of approximately 148 kDa. The antibody is composed of two heavy chains and two light chains, each containing a variable and constant region.
The variable region of Levilimab Biosimilar is responsible for its specificity and binding to IL6R. It recognizes and binds to the extracellular domain of IL6R, preventing the binding of interleukin-6 (IL-6) and subsequent signaling through the IL-6/IL6R complex. This inhibits the pro-inflammatory effects of IL-6, making Levilimab Biosimilar a potential therapeutic for IL-6 driven diseases.
The main activity of Levilimab Biosimilar is its ability to block the IL-6 signaling pathway. IL-6 is a cytokine that plays a crucial role in the immune response, inflammation, and tissue regeneration. However, dysregulation of IL-6 signaling has been linked to various diseases, including rheumatoid arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome (CRS).
By binding to IL6R, Levilimab Biosimilar prevents the binding of IL-6 and inhibits its downstream signaling. This leads to a decrease in the production of pro-inflammatory cytokines and chemokines, as well as a reduction in the recruitment and activation of immune cells. Overall, Levilimab Biosimilar helps to restore the balance of the immune system and reduce inflammation.
Levilimab Biosimilar has shown promising results in pre-clinical and clinical studies as a potential therapeutic for various inflammatory and autoimmune diseases. Some of the potential applications of Levilimab Biosimilar include:
Rheumatoid Arthritis (RA) RA is a chronic autoimmune disease characterized by inflammation of the joints, leading to pain and stiffness. IL-6 has been identified as a key player in the pathogenesis of RA. Levilimab Biosimilar has shown efficacy in reducing the signs and symptoms of RA in clinical trials, making it a potential treatment option for this disease.
CRS is a severe and potentially life-threatening complication that can occur in response to certain immunotherapies. It is characterized by an excessive release of pro-inflammatory cytokines, including IL-6. Levilimab Biosimilar has shown promising results in reducing the severity of CRS in pre-clinical studies, making it a potential treatment for this condition.
SJIA is a rare form of juvenile idiopathic arthritis (JIA) that is characterized by systemic inflammation and high levels of IL-6. Levilimab Biosimilar has shown efficacy in reducing the symptoms of SJIA in clinical trials, making it a potential treatment option for this disease.
IL-6 has been implicated in the pathogenesis of various other inflammatory and autoimmune diseases, such as psoriasis, Crohn’s disease
ProteoGenix catalogue number PX-TA1545. For research use only.
Target: Levilimab Biosimilar – Anti-IL6R mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Levilimab Biosimilar – Anti-IL6R mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
